Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

Published:2014-01-28 Issue:5 Volume:110 Page:1163-1168
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Kurokawa Y,Sugimoto N,Miwa H,Tsuda M,Nishina S,Okuda H,Imamura H,Gamoh M,Sakai D,Shimokawa T,Komatsu Y,Doki Y,Tsujinaka T,Furukawa H

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201418.pdf

Reference20 articles.

1. Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.

2. Choi IS, Lee KW, Kim KH, Kim YJ, Kim JH, Lee JS (2010) Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Med Oncol 27: 992–997.

3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36–46.

4. Diasio RB (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park) 13: 17–21.

5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228–247.

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic, Prognostic, and Predictive Biomarkers in Gastric Cancer: from Conventional to Novel Biomarkers;Translational Research;2024-09

2. Biomarker-oriented chemo-immunotherapy for advanced gastric cancer;International Journal of Clinical Oncology;2024-04-22

3. Advances in the Theranostics of Oesophageal Squamous Carcinoma;Advanced Therapeutics;2023-04-16

4. Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022;Human Vaccines & Immunotherapeutics;2023-01-02

5. Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination;Journal of Gastric Cancer;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3